[COVID-19: Still a place for tocilizumab?]

[Article in French]

Q Richier¹, L Plaçais², K Lacombe³, O Hermine⁴

Affiliations

¹ Service de maladies infectieuses, hôpital Saint-Antoine, Assistance publique des Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France. Electronic address: quentin.richier@hotmail.fr.
² Service d'hématologie, hôpital Necker, Assistance publique des Hôpitaux de Paris, Paris, France; Sorbonne université, Paris, France.
³ Service de maladies infectieuses, hôpital Saint-Antoine, Assistance publique des Hôpitaux de Paris, Paris, France; Sorbonne université, Paris, France.
⁴ Université de Paris, Paris, France; Service d'hématologie, hôpital Necker, Assistance publique des Hôpitaux de Paris, Paris, France; Inserm U 1163, institut Imagine, Paris, France.

PMID: 33288230
PMCID: PMC7691818
DOI: 10.1016/j.revmed.2020.11.016

Review

[COVID-19: Still a place for tocilizumab?]

[Article in French]

Q Richier et al. Rev Med Interne. 2021 Feb.

. 2021 Feb;42(2):73-78.

doi: 10.1016/j.revmed.2020.11.016. Epub 2020 Nov 27.

Authors

Q Richier¹, L Plaçais², K Lacombe³, O Hermine⁴

Affiliations

¹ Service de maladies infectieuses, hôpital Saint-Antoine, Assistance publique des Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France. Electronic address: quentin.richier@hotmail.fr.
² Service d'hématologie, hôpital Necker, Assistance publique des Hôpitaux de Paris, Paris, France; Sorbonne université, Paris, France.
³ Service de maladies infectieuses, hôpital Saint-Antoine, Assistance publique des Hôpitaux de Paris, Paris, France; Sorbonne université, Paris, France.
⁴ Université de Paris, Paris, France; Service d'hématologie, hôpital Necker, Assistance publique des Hôpitaux de Paris, Paris, France; Inserm U 1163, institut Imagine, Paris, France.

PMID: 33288230
PMCID: PMC7691818
DOI: 10.1016/j.revmed.2020.11.016

No abstract available

Keywords: COVID-19; Hyperinflammation; Interleukin-6; Interleukine-6; SARS-COV-2; SARS-CoV-2; Tocilizumab.

PubMed Disclaimer

References

1. Lauer S.A., Grantz K.H., Bi Q., Jones F.K., Zheng Q., Meredith H.R. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med. 2020;172(9):577–582. - PMC - PubMed
1. Byambasuren O., Cardona M., Bell K., Clark J., McLaws M.-L., Glasziou P. Estimating the extent of asymptomatic COVID-19 and its potential for community transmission: systematic review and meta-analysis. Can J Infect Dis Med Microbiol. 2020 doi: 10.3138/jammi-2020-0030. - DOI - PMC - PubMed
1. He X., Lau E.H.Y., Wu P., Deng X., Wang J., Hao X. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med. 2020;26(5):672–675. - PubMed
1. Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. - PMC - PubMed
1. Wu C., Chen X., Cai Y., Xia J., Zhou X., Xu S. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan. China. JAMA Intern Med. 2020;180(7):934–943. - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

[COVID-19: Still a place for tocilizumab?]

Affiliations

[COVID-19: Still a place for tocilizumab?]

Authors

Affiliations

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Miscellaneous